CEO INVESTOR CONFERENCE February 13-14, 2017 • The Waldorf Astoria New York bio.org/CEO • #BIOCEO16 bio.org/CEO • #BIOCEO17 CEO INVESTOR CONFERENCE Now in its 19th year, the BIO CEO & Investor Conference WHY ATTEND? is one of the largest investor • EXPERIENCE the largest, unbiased forum where institutional conferences focused on investors, industry analysts, and senior biotechnology executives shape the future investment landscape of the industry. established and emerging publicly traded and select • HEAR Washington’s perspective on how the Trump Administration will address ACA, CMS and PDUFA VI. private biotech companies. • EVALUATE fresh investment opportunities including compatible, complementary and competitive companies. • LEARN about the hottest clinical developments and industry catalysts by attending the conference’s therapeutic workshops and business roundtables. • ATTEND fireside chats with CEOs who will share their recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2017. • GAIN ACCESS to BIO’s One-on-One Partnering system for scouting potential investments and deal partners, optimizing your time at the event. • HEAR presentations from more than 175 established public and private biotech companies and non-profit funding organizations, including many you won’t hear from at other investor conferences. • GET THE PULSE of the current and proposed investment trends in biotechnology. • NETWORK with peers, investors, and potential partners attending the conference and our exclusive receptions. 2 bio.org/CEO CEO INVESTOR CONFERENCE 2017 FIRESIDE CHAT SPEAKERS Fireside Chats feature candid discussions between biopharma executives, Wall Street analysts, and other high-level industry experts. Hear about recent company Giovanni Caforio, MD Tony Coles, MD Chief Executive Officer, Chairman and Chief successes, what keeps the Bristol-Myers Squibb Executive Officer, C-suite up at night, and Yumanity Therapeutics where the industry’s leading companies are headed in 2017. Jeffrey D. Marrazzo J. Joseph Kim, PhD Co-Founder and Chief President and Chief Executive Officer, Executive Officer, Spark Therapeutics Inovio Pharmaceuticals Lynn Seely, MD Chief Executive Officer, Myovant Sciences #BIOCEO17 3 2017 AGENDA APPLYING MICROBIOME RESEARCH SPEAKERS Joseph Pearlberg, MD, Vice President Clinical TO THERAPEUTICS Development, Infinity Pharmaceuticals, Inc. Monday • February 13, 2017 • 9:00 am – 9:55 am Jeffrey Wolf, Chief Executive Officer, Heat Biologics New discoveries are finding links that extend significantly Anton Xavier, Senior Scientist, Pfizer Inc. beyond the gut microbiome and intestinal disorders into a range of bodily systems including the immune and nervous systems. Jerome Zeldis, MD, PhD, Chief Medical Officer Major biopharma companies have engaged in significant deals and President of Clinical Development, Sorrento that envision treatments to commercialize from this research Therapeutics and leading companies are pushing forward on clinical trials. This session will outline the microbiome influenced therapies NEXT GENERATION PAIN CONTROL: most likely to create major effects for patients. BEYOND OPIOIDS MODERATOR: C. Simone Fishburn, PhD, Editor, Monday • February 13, 2017 • 1:30 pm – 2:25 pm BioCentury Innovations The scourge of rising addiction and heroin overdoses has SPEAKERS Pierre Belichard, PharmD, PhD, Chief been associated with the growth in usage of important, opioid- Executive Officer, Enterome based, prescription pain treatments. New approaches to pain Mark Bodmer, PhD, Chief Scientific Officer, control are looking at different biological mechanisms and Evelo Biosciences methodologies for improving patients’ lives with lower risks of ill effects or addiction. This session will speak with experts Aoife M. Brennan, MD, Chief Medical Officer, Synlogic developing therapeutic innovations that do not rely on opioid- based drugs and can provide doctors additional alternatives for Nick Conley, PhD, Board of Directors, helping patients. Co-founder & Chief Executive Officer, EpiBiome Jeffrey Riley, Chief Executive Officer, President MODERATOR: Corey Davis, PhD, Managing Director, Senior and Director, Synthetic Biologics Healthcare Analyst, H.C. Wainwright & Co., LLC Nikola Trbovic, PhD, Director R&D Technology SPEAKERS Gail Cawkwell, MD, Chief Medical Officer, Strategy, Worldwide Research & Development, Purdue Pharma L.P. Pfizer Inc. Derek Chalmers, PhD, DSc, Chief Executive Officer, President, and Director, Cara Therapeutics FIRESIDE CHAT WITH J. JOSEPH KIM, PHD Russell Herndon, President and Chief President and Chief Executive Officer, Executive Officer, Hydra Biosciences Inovio Pharmaceuticals Jeffrey B. Kindler, Chief Executive Officer, Monday • February 13, 2017 • 10:00 am – 10:55 am Centrexion Therapeutics MODERATOR Phyllis A. Arthur, Managing Director, Infectious Diseases and Diagnostics Policy, Biotechnology FIRESIDE CHAT WITH TONY COLES, MD Innovation Organization Chairman and Chief Executive Officer, Yumanity Therapeutics Monday • February 13, 2017 • 2:30 pm – 3:25 pm CAR-T, TILS, AND BISPECIFICS: IMMUNO- MODERATOR Ian Woo, Managing Director, Lazard ONCOLOGY CHALLENGES AND OPPORTUNITIES Monday • February 13, 2017 • 11:00 am – 11:55 am The maturation of new cancer treatment technologies has IPOS AND BEYOND: TAPPING INTO THE PUBLIC produced a mix of highly positive patient outcomes and some MARKET’S CAPITAL serious clinical holds, while investments for manufacturing and Monday • February 13, 2017 • 3:30 pm – 4:25 pm commercialization continue to accelerate. This session will dive As biotech IPO activity has cooled from its 2015 peak, into the assumptions underlying the most aggressive approaches companies are more deliberately weighing reverse mergers and the ways of reducing the risks of failure along the way to and other alternatives to benefiting from the capital in public delivering immuno-oncology’s promise to patients broadly. markets. With post-election market uncertainty, does the IPO MODERATOR: Michael King, Managing Director and Senior market for 2017 seek to rise, fall, or stay level? What markers Research Analyst, JMP Securities should CEOs watch for to gauge their timing and choices? 4 bio.org/CEO CEO INVESTOR CONFERENCE This session will feature experienced voices for explaining the EMBEDDING DIVERSITY INTO BOARD AND practical techniques for getting into public markets and what EXECUTIVE TEAM RECRUITMENT investors are expecting to see in order to win their support. Tuesday • February 14, 2017 • 10:00 am – 10:55 am MODERATOR Stephen B. Thau, Partner, Morrison & The biopharma industry has seen enormous growth in recent Foerster LLP years of the number of start-ups and IPOs, with hundreds of SPEAKERS James Cappuccio, Managing Director, new executive team and board member positions being filled. Investment Banking, H.C. Wainwright & Co., LLC However, the inclusion of underrepresented groups in these Brian Hagerty, Senior Director, Head of influential positions has failed to keep pace with the growth of Healthcare Capital Markets, New York biopharma companies and too often the decision-makers fail Stock Exchange to reflect the employee bases they lead or patient populations Douglas E. Onsi, Chief Financial Officer, they serve. This session will focus on practical approaches and Leap Therapeutics, Inc. successful examples to improve the diversity of leadership recruitment efforts and better align organizations with the full Sapna Srivastava, PhD, former Chief Financial measure of talented people available. Officer and Chief Strategy Officer, Intellia Therapeutics MODERATOR Julie L. Gerberding, MD, MPH, Executive Vice Nassim Usman, PhD, President and Chief President & Chief Patient Officer, Strategic Executive Officer, Catalyst Biosciences Communications, Global Public Policy and Population Health, Merck FIRESIDE CHAT WITH LYNN SEELY, MD SPEAKERS Colleen Cuffaro, PhD, Principal, Canaan President and Chief Executive Officer, Myovant Sciences Partners Monday • February 13, 2017 • 4:30 pm – 5:25 pm Faith L. Charles, Partner, Chair, Life Sciences, Thompson Hine LLP/ Chair, Women in Bio— MODERATOR K.C. Stone, Managing Director, Head of Metro New York Healthcare Investment Banking BTIG , Linda S. Grais, MD, President and Chief Executive Officer, Ocera Therapeutics, Inc. LIVING WITH BIOSIMILARS: STRATEGY Paul J. Hastings, Chairman and Chief Executive FORMULATION AND LESSONS FROM Officer, OncoMed Pharmaceuticals OTHER MARKETS Stephen M. Ritoch, Chairman of the Board and Chief Executive Officer, Blaise GroupFaith Tuesday • February 14, 2017 • 9:00 am – 9:55 am As biosimilar medicine options begin to roll-out in the United FIRESIDE CHAT WITH JEFFREY D. MARRAZZO, States, the regulatory and legal uncertainties are also starting Co-Founder and Chief Executive Officer, Spark to shrink below the market adoption uncertainties. As some Therapeutics innovator companies also pursue biosimilar development, and others seek to compete, there are opportunities to learn from Tuesday • February 14, 2017 • 11:00 am – 11:55 am jurisdictions that have allowed biosimilar medicines for longer MODERATOR Erin McCallister, Senior Editor, BioCentury periods, such as Japan and Europe regarding the reactions Publications of doctors and payers. This session will feature executives from innovator companies explaining how they evaluate biosimilars within their pipelines, plus those with expertise on POLICY OUTLOOK—ACA, CMS, PDUFA VI AND understanding the economic effects seen